RocheRocheSecond time around: Roche’s return to MediLink underlines the value of the first dealRoche is back in China — and this time at a very different price point. In a renewed partnership with MediLink Therapeutics, the Swiss pharmaceutical group has secured a second antibody–drug conjugate … more ➔
Freepik.comJohnson & JohnsonNumab’s billion-dollar antibody deal takes an unexpected turnJust over a year and a half ago, Swiss biotech Numab AG, based in Horgen on Lake Zurich, made the headlines when it sold a single antibody to Johnson & Johnson for US$1.25 billion via a spin-out vehicle. … more ➔
Bayer AGCovid-19Better late than never: Bayer eyes a slice of the mRNA vaccine piePatent disputes are part of everyday life in pharma. What is unusual is the timing. More than three years after the peak of the Covid-19 pandemic, Bayer has launched a broad patent offensive against … more ➔
Seed financingEnodia Therapeutics raises €20.7m seed round for targeted protein degradation pipelineParis-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation. Elaia, Pfizer Ventures and Bpifrance led the … more ➔
Picture from Ferdinand Stöhr on Unsplash Series A financing French investor Andera makes a $227m bet on U.S. obesity and asthma innovationParis-based private equity firm Andera Partners has kicked off 2026 with a surge of cross-border activity, leading two significant Series A financings for U.S. life sciences ventures. The back-to-back … more ➔
Photo from Giulia Bertelli on Unsplash Seed financingTECregen raises €11m seed round to advance thymus regenerationSwiss biotechnology company TECregen, based in Basel, has raised CHF 10 million (about €11 million) in seed financing to advance therapies designed to restore immune function by regenerating the thymus, … more ➔
EngitixFundraisingBillionaire Mike Platt backs Engitix for the second time with a $25 million series A extension4 years after its initial series A round, Engitix has completed a $25 million series A extension, led by Netherton Investments, which invests on behalf of billionaire hedge fund founder Mike Platt. The … more ➔
Evotec SEAcquisitionEvotec benefits from Dark Blue acquisition by AmgenThe acquisition of Oxford-based Dark Blue Therapeutics by US biotechnology company Amgen Inc. has produced a German beneficiary: Hamburg-based Evotec SE. Through an early collaboration with the Oxford … more ➔
CollaborationBasilea strikes up to $48.5m antifungal deal with U.S. biotech ProkaryoticsSwiss anti-infectives specialist Basilea Pharmaceutica has entered a research collaboration with U.S.-based Prokaryotics to develop a novel broad-spectrum antifungal aimed at treating severe invasive … more ➔
Clinical trialPolish biotech JPP Biologics reports positive Phase I data for first-in-class biologic for immune diseasesJJP Biologics has announced positive top-line results from a Phase I clinical trial of JJP-1212, its first-in-class anti-CD89 antagonist being developed for IgA-mediated inflammatory diseases. The data … more ➔
Roche
Freepik.com
Bayer AG
Picture from Ferdinand Stöhr on Unsplash 
Photo from Giulia Bertelli on Unsplash 
Engitix
Evotec SE
